Arcus Biosciences, Inc. (RCUS) Q3 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon. Thank you for attending today's Arcus Biosciences third quarter 2024 earnings call. My name is Tamia and I will be your moderator for today's call. All lines will be muted during the presentation portion of the call with an opportunity for questions and answers at the end. If you would like to ask a question, please press star one on your telephone keypad. I would now like to pass the conference over to your host, Tia Eves, Vice President of Investor Relations. You may proceed. Hello everyone, and thank you for joining us on today's conference call to discuss our third quarter, 2024 financial results and pipeline updates, including our upcoming presentation of our 10 data at 50. I'd like to remind you that on this call management will make forward looking statements, including statements about our cash runway and our expected clinical development milestones and timelines all statements other than historical facts. reflect the current beliefs and expectations of management, and involve risks and uncertainties that may cause our actual results to differ from those expressed. Those risks and uncertainties are described in our most recent quarterly report on Form 10-Q that has been filed with the SEC. Today, you'll hear from our CEO, Terry Rosen, CMO, Dimitri Naughton, COO, Jennifer Jarrett, and CFO, Bob Galtz. We'll also be joined by our President, Juan Jaen, for questions after the prepared remarks. With that, I'll turn the call over to Terry. Thank you very much, Pia, and thank you all for joining us today. As we head into 2025, our highest priority is to launch our late-stage development program for our HIF-2-alpha inhibitor, Cas-Statafan. As you know, just two weeks ago, we presented initial data from our ARC-20 study, evaluating Cas in late-line cle...